Protein deep sequencing applied to biobank samples from patients with pancreatic cancer
- 992 Downloads
Pancreatic cancer is commonly detected at advanced stages when the tumor is no longer amenable to surgical resection. Therefore, finding biomarkers for early stage disease is urgent. Here, we show that high-definition mass spectrometry (HDMSE) can be used to identify serum protein alterations associated with early stage pancreatic cancer.
We analyzed serum samples from patients with resectable pancreatic cancer, benign pancreatic disease, and healthy controls. The SYNAPT G2-Si platform was used in a data-independent manner coupled with ion mobility. The dilution of the samples with yeast alcohol dehydrogenase tryptic digest of known concentration allowed the estimated amounts of each identified protein to be calculated (Silva et al. in Anal Chem 77:2187–2200, 2005; Silva et al. in Mol Cell Proteomics 5:144–156, 2006). A global protein expression comparison of the three study groups was made using label-free quantification and bioinformatic analyses.
Two-way unsupervised hierarchical clustering revealed 134 proteins that successfully classified pancreatic cancer patients from the controls, and identified 40 proteins that showed a significant up-regulation in the pancreatic cancer group. This discrimination reliability was further confirmed by principal component analysis. The differentially expressed candidates were aligned with protein network analyses and linked to biological pathways related to pancreatic tumorigenesis. Pancreatic disease link associations could be made for BAZ2A, CDK13, DAPK1, DST, EXOSC3, INHBE, KAT2B, KIF20B, SMC1B, and SPAG5, by pathway network linkages to p53, the most frequently altered tumor suppressor in pancreatic cancer.
These pancreatic cancer study candidates may provide new avenues of research for a noninvasive blood-based diagnosis for pancreatic tumor stratification.
KeywordsEarly detection High-definition mass spectrometry Ion mobility Pancreatic cancer Serum biomarkers
- Charrier A, Chen R, Chen L, Kemper S, Hattori T, Takigawa M et al (2014) Connective tissue growth factor (CCN2) and microRNA-21 are components of a positive feedback loop in pancreatic stellate cells (PSC) during chronic pancreatitis and are exported in PSC-derived exosomes. Journal of cell communication and signaling. doi:10.1007/s12079-014-0220-3 PubMedCentralPubMedGoogle Scholar
- Dangi-Garimella S, Sahai V, Ebine K, Kumar K, Munshi HG (2013) Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression. PLoS ONE 8:e64566. doi:10.1371/journal.pone.0064566 PubMedCentralPubMedCrossRefGoogle Scholar
- Decker GA, Batheja MJ, Collins JM, Silva AC, Mekeel KL, Moss AA et al (2010) Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (NY) 6:246–254Google Scholar
- Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch M et al (2014) Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 289:3869–3875. doi:10.1074/jbc.C113.532267 PubMedCrossRefGoogle Scholar
- Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y et al (2013) Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg 258:336–346. doi:10.1097/SLA.0b013e3182827a65 PubMedCrossRefGoogle Scholar
- Postepska-Igielska A, Krunic D, Schmitt N, Greulich-Bode KM, Boukamp P, Grummt I (2013) The chromatin remodelling complex NoRC safeguards genome stability by heterochromatin formation at telomeres and centromeres. EMBO Rep 14:704–710. doi:10.1038/embor.2013.87 PubMedCentralPubMedCrossRefGoogle Scholar
- Rodriguez-Suarez E, Hughes C, Gethings L, Giles K, Wildgoose J, Stapels M et al (2013) An ion mobility assisted data independent LC-MS strategy for the analysis of complex biological samples. Curr Anal Chem 9:199–211Google Scholar
- Suzuki N, Hazama S, Ueno T, Matsui H, Shindo Y, Iida M et al (2014) A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J Immunother 37:36–42. doi:10.1097/CJI.0000000000000012 PubMedCentralPubMedCrossRefGoogle Scholar